Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden heart risks in Wilson's disease: a new scan could spot them early

NCT ID NCT07765472

Knowledge-focused Sponsor: Hebatullah Fawzy Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 14, 2026 · Last updated Aug 14, 2026

Summary

This study investigates whether children with Wilson's disease, who appear to have normal heart function, may actually have subtle heart problems. Using advanced echocardiography, ECG, and a blood test for a heart stress marker, researchers will compare these children to healthy peers. The goal is to see if these tests can detect early signs of heart involvement, which could improve monitoring and care for this condition.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Echocardiography, electrocardiography, and a blood test for pro-BNP
What this could lead to
If successful, this could lead to earlier detection and monitoring of heart issues in children with Wilson's disease, potentially improving long-term outcomes.
What could go wrong
This is a small, observational study, so results may not apply to all patients. It aims to find early signs, not to test a treatment, so it won't directly change care yet.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 72 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2025

Expected to finish

Nov 2026

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

They will be divided in to 2 groups: - Group 1: Patients confirmed Wilson's disease. - Group 2: Controls. * Patients group: Patient diagnosed as WD patients, following up in Pediatric Hepatology Clinic in NHTMRI. According to Criteria of diagnosis based on Leipzig scoring system (11,12): Typical clinical symptoms and signs, as: Kayser-Fleischer rings, neurological symptoms, serum ceruloplasmin, Coombs-negative hemolytic anemia. Other tests: Liver biopsy, 24hr urinary Cu, gene analysis.

Ages

4 to 18 years

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria 1. Confirmed diagnosis of Wilson's disease based on Leipzig scoring criteria (including clinical signs, Kayser-Fleischer rings, low ceruloplasmin, or genetic analysis). 2. Age between 4 years and 18 years. 3. Written informed consent obtained from parents or legal guardians. Exclusion Criteria 1. Children with clinical evidence of overt heart failure or known congenital heart disease. 2. Children suffering from fulminant hepatitis. 3. Known co-existing primary liver diseases other than Wilson's disease. 4. Presence of syndromic disorders or major congenital anomalies.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Children are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Ventricular Dysfunction, Left Wilson disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Children Electrocardiographic changes Myocardial dysfunction Speckle tracking echocardiography Wilson disease Wilson's disease

Contacts and locations

Locations

  • Faculty of medicine AinShams U

    Cairo, Egypt

  • National Hepatology and Tropical Research Institute (NHTMRI)

    Giza, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.